Interleukin-2 in Treating Patients With Metastatic Melanoma

Status unconfirmed · Phase 2

Conditions studied: Melanoma (Skin)

In brief

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients who have metastatic melanoma.

Key facts

Study ID

NCT00002845

Run by

Blumenthal Cancer Center at Carolinas Medical Center

People needed

20

Starts

1995-09-01

Last updated by the study team

2013-12-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Carolinas Medical Center — Charlotte, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.